[Antibody therapies for melanoma]

Area of Science:

• Oncology
• Immunology

Background:

• Melanoma is highly immunogenic, yet immunotherapies achieve objective responses in less than 5% of patients.
• The tumor microenvironment exhibits suppressive immunoreactions, highlighting immunosuppressive molecules as potential therapeutic targets.

Purpose of the Study:

• To explore the potential of antibody-based immunotherapies for melanoma treatment.
• To review promising immunomodulating agents targeting immunosuppression in melanoma.

Main Methods:

• Review of existing literature on immunotherapies for melanoma.
• Focus on antibody therapies targeting cytotoxic T-lymphocyte antigen (CTLA)-4, PD-1, CD137, and CD40.

Main Results:

• Ipilimumab (anti-CTLA-4) showed objective responses and prolonged survival in phase 3 studies.
• PD-1 blockade demonstrated durable antitumor reactivity with improved safety.
• Anti-CD137 and anti-CD40 agonist antibodies are identified as potential therapeutic candidates.

Conclusions:

• Immunomodulating therapies, including ipilimumab and PD-1 blockade, are highly promising for overcoming melanoma-associated immunosuppression.
• Targeting immunosuppressive molecules represents a key strategy for advancing melanoma treatment.